background
hepat
steatosi
recogn
major
risk
factor
liver
diseas
progress
impair
respons
interferon
base
therapi
chronic
hepat
c
chc
patient
mechan
respons
interferonalpha
therapi
condit
hepat
steatosi
unexplor
investig
effect
hepatocellular
steatosi
hepat
c
viru
hcv
replic
antivir
respons
cell
cultur
model
method
subgenom
replicon
hcv
infect
cell
cultur
mixtur
satur
palmit
unsatur
oleat
longchain
free
fatti
acid
ffa
intracytoplasm
fat
accumul
cell
visual
nile
red
stain
electron
microscopi
quantifi
microfluorometri
effect
ffa
treatment
hcv
replic
antivir
respons
measur
flow
cytometr
analysi
renilla
luciferas
activ
realtim
rtpcr
result
ffa
treatment
induc
dose
depend
hepatocellular
steatosi
lipid
droplet
accumul
hcv
replicon
cell
confirm
nile
red
stain
microfluorometri
electron
microscopi
intracellular
fat
accumul
support
replic
persist
hcv
infect
cultur
subgenom
replicon
cell
line
ffa
treatment
also
partial
block
respons
viral
clearanc
reduc
phosphoryl
depend
promot
activ
show
ffa
treatment
induc
endoplasm
reticulum
er
stress
respons
regul
chain
type
ifn
receptor
lead
defect
jakstat
signal
impair
antivir
respons
conclus
result
suggest
intracellular
fat
accumul
hcv
cell
cultur
induc
er
stress
defect
jakstat
signal
attenu
antivir
respons
thu
provid
explan
clinic
observ
regard
hepatocellular
steatosi
influenc
respons
chc
hepat
c
viru
hcv
infect
affect
estim
million
peopl
worldwid
one
major
caus
chronic
liver
diseas
liver
cirrhosi
hepatocellular
carcinoma
standard
care
chronic
hcv
genotyp
infect
includ
combin
interferonalpha
ribavirin
one
proteas
inhibitor
either
telaprevir
boceprevir
tripl
combin
therapi
greatli
improv
sustain
antivir
respons
among
chronic
hcv
patient
howev
larg
percentag
chronic
hcv
patient
still
unabl
clear
infect
regimen
predictor
sustain
virolog
respons
svr
interferon
base
combin
therapi
link
host
genet
factor
genotyp
viral
load
viral
genotyp
bodi
weight
stage
liver
diseas
obes
diabet
mellitu
dm
fibrosi
stage
coinfect
human
immunodefici
viru
understand
mechan
ribavirin
action
significantli
increas
due
avail
hcv
cell
cultur
system
group
shown
effici
inhibit
replic
hcv
cell
cultur
model
therefor
hcv
cell
cultur
model
provid
excel
vitro
model
system
assess
contribut
number
host
relat
factor
mechan
resist
number
clinic
studi
report
overweight
obes
hcvinfect
individu
steatosi
liver
higher
risk
nonrespons
preval
hepat
steatosi
chronic
hepat
c
patient
report
vari
associ
excess
alcohol
drink
increas
bodi
weight
dm
metabol
diseas
increas
lipogenesi
free
fatti
acid
ffa
overflow
hepatocyt
propos
major
caus
hepat
steatosi
chronic
hcv
infect
also
lead
abnorm
lipid
metabol
insulin
resist
factor
also
increas
risk
dm
data
support
fact
patient
high
bodi
mass
index
lower
chanc
svr
molecular
mechan
explain
hepat
steatosi
relat
metabol
liver
diseas
reduc
svr
unknown
palmit
oleic
acid
abund
ffa
liver
triglycerid
patient
nonalcohol
fatti
liver
diseas
studi
carri
examin
effect
cocultur
mixtur
two
ffa
hcv
replic
antivir
respons
use
stabl
subgenom
replicon
fulllength
hcv
infect
cell
cultur
show
ffa
treatment
hcv
cell
cultur
induc
hepatocellular
steatosi
lipid
accumul
dose
depend
manner
intracellular
fat
accumul
hcv
cell
cultur
increas
viral
replic
partial
block
antivir
respons
present
experiment
evid
indic
intracellular
lipid
accumul
induc
er
stress
respons
regul
chain
type
interferon
receptor
lead
creation
defect
jakstat
signal
impair
antivir
respons
hcv
stabl
replicon
cell
line
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
mm
lglutamin
sodium
pyruv
nonessenti
amino
acid
uml
penicillin
mg
ml
streptomycin
fetal
bovin
serum
supplement
nile
red
sodium
oleat
sodium
palmit
fatti
acid
free
bovin
serum
albumin
bsa
obtain
sigma
chemic
co
saint
loui
mo
recombin
human
intron
purchas
schere
plough
kenilworth
nj
cell
line
obtain
laboratori
charli
rice
rockefel
univers
new
york
maintain
dmem
fb
protein
lysat
replicon
cell
prepar
treatment
ffa
equal
amount
protein
resolv
sdspage
gel
antibodi
total
betaactin
pkr
perk
bip
antimous
igg
antirabbit
igg
hrplink
antibodi
purchas
cell
signal
beverli
antibodi
interferon
alphareceptor
purchas
santa
cruz
biotechnolog
santa
cruz
ca
antibodi
ppkr
obtain
epitom
burlingam
ca
mous
monoclon
antibodi
kindli
provid
biogen
idec
inc
cambridg
usa
use
formul
ffa
mixtur
ratio
oleat
palmit
mimic
benign
chronic
steatosi
low
toxic
describ
investig
briefli
mm
palmit
sigma
catalog
mm
oleat
sigma
catalog
stock
prepar
naoh
filter
steril
five
percent
wv
ffafre
bsa
solut
prepar
doubl
distil
water
filter
steril
mm
stock
solut
fatti
acid
prepar
bsa
solut
distil
water
mixtur
cool
room
temperatur
two
ffa
first
mix
togeth
growth
medium
steril
environ
laminar
flow
final
concentr
ffa
mm
bsa
cell
cultur
dish
confluenc
cocultur
differ
concentr
ffa
hour
induc
steatosi
indic
time
point
cell
wash
pb
cultur
regular
growth
medium
contain
fb
intracellular
fat
accumul
hcv
cell
cultur
determin
nile
red
stain
describ
briefli
hepatocyt
monolay
wash
twice
phosphatebuff
salin
pb
incub
minut
nile
red
solut
concentr
mgml
pb
treatment
cell
monolay
wash
pb
counterstain
nuclear
stain
hoechst
dye
calbiochem
darmstadt
germani
concentr
prepar
pb
cell
examin
fluoresc
microscop
describ
previous
intracellular
fat
content
quantit
use
microfluoromet
excit
nm
emiss
nm
intracellular
fat
accumul
ffa
treat
cell
also
confirm
electron
microscopi
use
standard
protocol
effect
ffa
treatment
cell
prolifer
measur
use
mtt
colorimetr
assay
assay
use
tetrazolium
compound
tetrazolium
bromid
sigmaaldrich
st
loui
mo
reduc
intracellularli
formazan
mitochondri
dehydrogenas
enzym
percentag
cell
viabil
determin
comparison
untreat
control
effect
ffa
treatment
hcv
replic
express
measur
flow
analysi
describ
previous
briefli
replicon
cell
without
ffa
treatment
collect
h
posttreat
intracellular
gfp
express
quantifi
use
flow
cytomet
bd
lsr
ii
bd
bioscienc
analysi
express
cell
treat
similarli
process
use
antibodi
epitom
burlingam
ca
per
supplier
protocol
secondari
antibodi
alexa
fluor
procur
invitrogen
ca
histogram
gener
use
winmdi
version
softwar
scripp
edu
total
rna
isol
cell
use
gitc
method
realtim
rtpcr
carri
describ
fulllength
chimer
viru
encod
renilla
luciferas
kindli
provid
curt
h
hagedorn
univers
utah
school
medicin
salt
lake
citi
plasmid
linear
xba
extract
phenol
chloroform
precipit
ethanol
hcvrna
transcript
prepar
vitro
use
rna
polymeras
cell
electropor
hcv
rna
transfect
cell
cultur
complet
dmem
infect
assay
carri
use
supernat
hr
posttransfect
briefli
cell
infect
viru
moi
overnight
follow
day
infect
cultur
wash
pb
incub
ml
dmem
fb
infect
cell
cultur
longterm
split
ratio
fiveday
interv
replic
hcv
infect
cell
cultur
interv
confirm
measur
renilla
luciferas
activ
hcv
rna
level
rtqpcr
renilla
luciferas
activ
measur
cell
lysat
use
luciferas
assay
kit
promega
total
protein
measur
use
bradford
assay
effect
ffa
treatment
jakstat
signal
pisrefirefli
luciferas
promot
activ
examin
use
publish
protocol
activ
measur
cotransfect
addgen
cambridg
dna
along
prltk
plasmid
cell
h
prior
ffa
treatment
cell
lysat
prepar
h
post
ffa
treatment
firefli
luciferas
valu
normal
renilla
luciferas
valu
infect
cell
mount
onto
glass
slide
via
cytospin
method
cell
wash
twice
mm
pb
ph
sigmaaldrich
st
loui
mo
minut
cell
fix
chill
aceton
minut
permeabil
treatment
reveal
decloak
rtu
biocar
medic
rv
minut
boil
point
slide
cool
room
temperatur
minut
block
perform
util
background
sniper
biocar
medic
minut
room
temperatur
cell
incub
monoclon
anticor
antibodi
thermo
scientif
pierc
hepat
c
viru
core
antigen
specif
mous
monoclon
antibodi
dilut
da
vinci
green
diluent
biocar
medic
hour
room
temperatur
follow
primari
antibodi
incub
cell
wash
time
tri
buffer
salin
ph
incub
mach
mous
probe
biocar
medic
minut
mous
probe
treat
cell
incub
hrp
polym
biocar
medic
minut
cell
wash
tb
time
next
cell
treat
diaminobenzidin
dab
chromogen
dako
cytom
carpinteria
ca
minut
slide
counterstain
hematoxylin
second
tacha
blu
solut
biocar
medic
htblu
second
dehydr
mount
observ
light
microscopi
microfluorometri
assay
result
isr
activ
transcript
factor
hcv
luciferas
activ
real
time
rtpcr
fac
analysi
compar
signific
use
student
test
p
valu
less
consid
signific
oleat
unsatur
palmit
satur
fatti
acid
mix
ratio
directli
ad
cell
cultur
medium
supplement
bsa
induc
steatosi
cell
cultur
concentr
satur
fatti
acid
nonsatur
fatti
acid
use
studi
compar
patholog
rang
human
nonalcohol
fatti
liver
diseas
first
cell
cultur
increas
concentr
ffa
hepatocellular
steatosi
confirm
fluoresc
microscopi
nile
red
stain
repres
pictur
show
ffa
treatment
result
dosedepend
intracellular
lipid
accumul
hcv
replicon
cell
visual
fluoresc
microscopi
figur
cell
treat
equimolar
concentr
bsa
carrier
protein
use
control
result
microscop
find
lipid
droplet
accumul
cytoplasm
hcv
cell
cultur
quantifi
microfluorometri
figur
concentrationdepend
toxic
effect
ffa
treatment
hcv
cell
cultur
determin
use
mtt
assay
figur
indic
increas
concentr
ffa
toxic
cell
mtt
assay
result
show
ffa
mixtur
caus
cellular
toxic
mm
longterm
stabil
toxic
intracellular
lipid
droplet
accumul
ffa
treat
hcv
cell
cultur
also
examin
kinet
studi
figur
suggest
ffa
mm
induc
fairli
high
level
hepatocellular
steatosi
cell
cultur
without
caus
appar
toxic
electron
microscop
studi
confirm
cell
cultur
ffa
develop
intracytoplasm
accumul
lipid
droplet
vicin
er
figur
base
result
hepatocellular
steatosi
hcv
cell
cultur
carri
use
highli
viabl
concentr
ffa
determin
impact
viru
replic
antivir
respons
determin
whether
intracellular
fat
accumul
play
role
modul
hcv
rna
replic
cultur
replicon
cell
differ
concentr
ffa
express
hcv
gfp
fusion
protein
monitor
use
fluoresc
microscopi
figur
quantifi
flow
cytometr
analysi
figur
mean
fluoresc
gfpposit
cell
follow
ffa
treatment
increas
compar
cell
treat
bsa
figur
increas
hcv
rna
level
cell
treatment
increas
concentr
ffa
measur
real
time
rtpcr
figur
replicon
base
hcv
cell
cultur
model
lack
structur
protein
cultur
produc
infecti
viru
therefor
effect
ffa
treatment
hcv
replic
examin
use
persist
infect
hcv
cell
cultur
system
replic
hcv
infect
cell
ffa
treatment
measur
use
renilla
luciferas
report
cell
infect
cell
cultur
deriv
viru
moi
overnight
incub
maintain
longterm
cultur
split
ratio
effect
longterm
shortterm
cultur
ffa
hcv
replic
measur
initi
determin
dose
depend
effect
ffa
treatment
hcv
replic
infect
cultur
short
term
hour
result
indic
intracellular
fat
accumul
infect
cell
cultur
result
dose
depend
increas
hcv
replic
measur
renilla
luciferas
activ
figur
second
set
experi
perform
determin
effect
longterm
cocultur
ffa
hcv
replic
infect
cell
cultur
purpos
persist
infect
cell
cultur
ffa
day
hcv
replic
cultur
without
ffa
treatment
measur
renilla
luciferas
activ
result
experi
show
statist
signific
increas
hcv
replic
concentr
ffa
figur
c
effect
ffa
treatment
hcv
replic
infect
cell
also
confirm
immunostain
core
protein
result
shown
figur
indic
hcv
core
immunostain
persist
infect
cell
cultur
ffa
day
show
intens
core
stain
compar
without
ffa
treatment
taken
togeth
result
indic
longterm
cultur
ffa
infect
cell
led
increas
hcv
replic
test
whether
intracellular
lipid
droplet
accumul
affect
respons
hcv
replic
use
replicon
infect
cell
cultur
model
replicon
cell
line
cultur
growth
medium
without
ffa
day
treat
addit
h
cell
also
cocultur
ffa
treat
titer
hcv
rna
replicon
cultur
quantifi
use
realtim
rtpcr
assay
indic
ffa
treatment
partial
block
antivir
effect
hcv
concentr
depend
manner
figur
effect
ffa
treatment
antivir
respons
confirm
use
persist
infect
hcv
cell
cultur
model
infect
cell
cocultur
differ
concentr
ffa
cultur
treat
h
replic
hcv
infect
cell
cultur
model
examin
renilla
luciferas
assay
result
shown
figur
indic
ffa
treatment
block
ifnantivir
respons
dose
depend
manner
infect
cell
treat
ffa
show
dose
depend
increas
renila
luciferas
activ
concentr
depend
antivir
effect
hcv
infect
cell
cultur
examin
presenc
absenc
ffa
treatment
figur
summari
result
support
ffa
treatment
block
antivir
action
replicon
infect
cell
cultur
result
statist
signific
find
explan
replicon
cell
cultur
ffa
show
impair
antivir
effect
examin
er
stress
pathway
recent
publish
report
suggest
ffa
treatment
induc
er
stress
respons
therefor
activ
three
independ
er
stress
pathway
includ
perk
rnadepend
protein
kinaselik
endoplasm
reticulum
kinas
inositol
requir
enzym
activ
transcript
factor
examin
result
shown
figur
indic
luciferas
activ
dosedepend
manner
ffatreat
cell
compar
untreat
cell
ffa
treatment
cell
induc
er
stress
relat
marker
bip
figur
level
kinas
like
perk
pkr
alter
ffa
treatment
ffa
treatment
also
increas
suppressor
cytokin
signal
level
explain
potenti
mechan
connect
er
stress
respons
defect
jakstat
signal
examin
cell
surfac
express
known
target
er
stress
mechan
express
level
replicon
cell
without
ffa
treatment
examin
western
blot
analysi
flow
cytometri
result
shown
figur
indic
ffa
treatment
result
reduc
express
examin
potenti
effect
er
stress
respons
ffa
ifninduc
jakstat
signal
measur
phosphoryl
downstream
protein
includ
western
blot
analysi
figur
phosphoryl
affect
significantli
depend
express
phosphoryl
unalt
intracellular
jakstat
signal
ffatreat
cell
also
examin
use
firefli
luciferas
report
plasmid
driven
promot
isreluc
promot
activ
significantli
affect
ffa
treatment
figur
histogram
cell
surfac
express
show
chang
peak
shift
left
ffatreat
cell
figur
mean
fluoresc
intens
mfi
ffatreat
cell
decreas
mm
ffa
result
suggest
ffa
treatment
block
mediat
activ
promot
activ
cell
thu
impair
antivir
action
standard
care
chronic
hcv
genotyp
infect
includ
plu
ribavirin
along
one
proteas
inhibitor
howev
result
clinic
studi
indic
sustain
virolog
respons
combin
therapi
impair
viral
host
relat
factor
viral
factor
play
import
role
treatment
respons
sinc
patient
infect
hcv
genotyp
show
poor
respons
compar
genotyp
addit
viru
genotyp
sever
hostrel
factor
also
affect
outcom
antivir
therapi
includ
viral
load
presenc
cirrhosi
age
race
metabol
diseas
obes
diabet
obes
risk
factor
result
poor
treatment
respons
pegyl
interferon
pegyl
interferon
combin
ribavirin
hepat
steatosi
develop
secondari
obes
dm
alcohol
abus
protein
malnutrit
carbohydr
overload
chronic
hcv
infect
hepat
steatosi
also
common
histopatholog
featur
chronic
hcv
infect
found
patient
report
indic
hcv
infect
induc
develop
hepatocellular
steatosi
block
releas
lowdens
lipoprotein
vldl
particl
liver
circul
report
number
investig
presenc
hepat
steatosi
patient
chronic
hcv
infect
affect
liver
diseas
progress
pathogenesi
treatment
respons
mechan
impair
respons
interferonbas
therapi
condit
hepat
steatosi
clearli
understood
took
advantag
hcv
cell
cultur
system
establish
liverderiv
cell
line
studi
mechan
antivir
respons
presenc
absenc
ffa
hepatocellular
steatosi
induc
hcv
replicon
cell
mixtur
satur
nonstatur
ffa
investig
use
ffa
cocktail
studi
pathogen
mechan
hepat
steatosi
cell
cultur
result
support
ffa
treatment
induc
steatosi
hcv
replicon
cell
dosedepend
manner
high
dose
ffa
treatment
hcv
cell
cultur
lead
increas
cell
toxic
cell
death
apoptosi
report
other
show
ffa
rang
increas
hcv
replic
infect
cell
cultur
support
data
publish
previous
result
suggest
intracellular
fat
accumul
partial
block
ifn
antivir
action
viral
clearanc
replicon
infect
cell
cultur
publish
report
laboratori
other
indic
cellular
jakstat
signal
critic
success
antivir
respons
hcv
result
provid
evid
support
ffa
treatment
hcv
cell
cultur
induc
er
stress
respons
block
cellular
jakstat
signal
regul
result
induc
phosphoryl
promot
activ
attenu
studi
laboratori
includ
shown
er
stress
correl
well
regul
cell
cultur
model
propos
futur
studi
conduct
determin
attenu
erstress
respons
pharmacolog
inhibitor
sirna
knockdown
improv
antivir
respons
condit
hepat
steatosi
retain
express
result
use
hcv
cell
cultur
provid
explan
mechan
chronic
hcv
patient
fatti
liver
show
impair
respons
ifn
ribavirin
treatment
regard
find
propos
model
chronic
hcv
patient
steatosi
increas
lipid
droplet
hepatocyt
block
interferondepend
jakstat
signal
figur
result
also
support
number
studi
role
express
correl
respons
therapi
chronic
hepat
c
studi
conduct
taniguchi
et
al
indic
high
intrahepat
mrna
level
among
chronic
hcv
patient
treatment
associ
favor
respons
ifn
therapi
anoth
studi
katsumi
et
al
report
express
rate
significantli
higher
respond
nonrespond
fujiwara
et
al
conduct
studi
express
receptor
respons
interferon
therapi
examin
chronic
hepat
c
patient
found
express
level
liver
predict
respons
treatment
chronic
hepat
c
patient
studi
meng
et
al
also
examin
express
receptor
liver
patient
chronic
hepat
c
ifn
respond
nonrespond
author
found
express
interferon
receptor
obviou
treatment
respons
group
nonrespons
group
welzel
et
al
analyz
relationship
variant
pathway
svr
among
particip
hepat
c
antivir
longterm
treatment
cirrhosi
haltc
trial
found
statist
signific
express
express
associ
respons
antivir
therapi
chronic
hcv
patient
addit
number
studi
provid
evid
suggest
mechan
may
involv
impair
respons
obes
patient
exampl
walch
et
al
found
increas
express
protein
associ
nonrespons
therapi
investig
propos
increas
express
figur
schemat
represent
show
intracellular
lipid
droplet
accumul
affect
jakstat
signal
two
possibl
mechan
intracellular
fat
accumul
induc
er
stress
relat
protein
bip
caus
phophoryl
lead
regul
express
reduc
express
affect
bind
jakstat
signal
downstream
antivir
respons
bind
cell
surfac
receptor
activ
phosphoryl
activ
requir
phosphoryl
bind
form
complex
transloc
nucleu
induc
ifnstimul
gene
express
ii
show
ffa
treatment
induc
also
inhibit
phosphoryl
also
block
tyrosin
phosphoryl
respons
stimul
also
found
level
increas
increas
data
shown
replicon
cell
treat
ffa
involv
also
anoth
possibl
mechan
intracellular
lipid
alter
jakstat
signal
vitro
find
suggest
ffainduc
er
stress
level
two
major
target
play
role
reduc
jakstat
signal
impair
antivir
respons
ffatreat
cell
